39.1p -3.2 -7.5%
Last Trade - 4:29pm
| Market Cap | ÂŁ65.9m |
| Enterprise Value | ÂŁ63.7m |
| Revenue | ÂŁn/a |
| Position in Universe | 1146th / 1807 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.29 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
SkinBioTherapeutics PLC is a life science company focused on skin health. The Company’s platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company’s SkinBiotix platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. It focuses on three specific skin healthcare sectors: cosmetics, infection control and eczema. In each of these areas, the Company plans to exemplify its technology in human studies. The Company’s program is focused on the application of the Skinbiotix platform in managing sensitive skin in the cosmetics industry. SkinBiotix increases the rate of skin healing in response to injury.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | June 10, 2015 |
| Public Since | April 5, 2017 |
| No. of Shareholders: | n/a |
| No. of Employees: | 7 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 155,889,922 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 15 1 Silk House Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom |
| Web | http://www.skinbiotherapeutics.com/ |
| Phone | +44 161 4682760 |
| Contact | () |
| Auditors | Jeffreys Henry LLP |
As of 4:29pm, shares in SkinBioTherapeutics are trading at 39.1p, giving the company a market capitalisation of ÂŁ65.9m. This share price information is delayed by 15 minutes.
Shares in SkinBioTherapeutics are currently trading at 39.1p and the price has moved by 0.277k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the SkinBioTherapeutics price has moved by 0.276k% over the past year.
There are no analysts currently covering SkinBioTherapeutics.
SkinBioTherapeutics is scheduled to issue upcoming financial results on the following dates:
SkinBioTherapeutics does not currently pay a dividend.
SkinBioTherapeutics does not currently pay a dividend.
SkinBioTherapeutics does not currently pay a dividend.
To buy shares in SkinBioTherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in SkinBioTherapeutics are currently trading at 39.1p, giving the company a market capitalisation of ÂŁ65.9m.
Here are the trading details for SkinBioTherapeutics:
Based on an overall assessment of its quality, value and momentum, SkinBioTherapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for SkinBioTherapeutics.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SkinBioTherapeutics. Over the past six months, the relative strength of its shares against the market has been 65.09%. At the current price of 39.1p, shares in SkinBioTherapeutics are trading at 95.57% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for SkinBioTherapeutics.
SkinBioTherapeutics's management team is headed by:
Here are the top five shareholders of SkinBioTherapeutics based on the size of their shareholding:
